3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hematologic Diseases
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bone Marrow Diseases
1
Abiraterone Acetate
1
Interventions
ruxolitinib
6
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Cytarabine
5
fludarabine phosphate
4
Whole-Body Irradiation
4
Methotrexate
4
Daunorubicin
4
Thioguanine
3
Tacrolimus
3
Etoposide
3
Early Intervention, Educational
3
Cyclophosphamide
3
ponatinib
2
parsaclisib
2
nilotinib
2
merphos
2
luspatercept
2
fludarabine
2
fedratinib
2
anagrelide
2
Tretinoin
2
Therapeutics
2
Psychiatric Rehabilitation
2
Mitoxantrone
2
Filgrastim
2
Cyclosporins
2
Cyclosporine
2
Busulfan
2
Asparaginase
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Myeloproliferative Disorders
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts